Phase 2 Study to Evaluate Efficacy and Safety of MR13A9 in Hemodialysis Patients with Uremic Pruritus.

Trial Profile

Phase 2 Study to Evaluate Efficacy and Safety of MR13A9 in Hemodialysis Patients with Uremic Pruritus.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Difelikefalin (Primary)
  • Indications Pruritus
  • Focus Therapeutic Use
  • Sponsors Maruishi Pharmaceutical
  • Most Recent Events

    • 07 Mar 2017 Planned End Date changed from 30 Apr 2017 to 31 Oct 2017.
    • 15 Dec 2016 Planned End Date changed from 28 Feb 2017 to 30 Apr 2017.
    • 01 Aug 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top